In very rapidly progressive/poorly differentiated hepatocellular cancer, would you use the targeted options (sorafenib/lenvatinib) or would you try a traditional cytotoxic regimen?

Topics: Gastrointestinal Cancers • Medical Oncology • Liver and Pancreas Tumors • NCI-CCC Tumor Board Question • University of Wisconsin • NCI-CCC GI Tumor Board Question

Answer from: Medical Oncologist at Community Practice

The approach to a patient with rapidly progressive hepatocellular cancer is quite challenging. Systemic chemotherapy is of marginal benefit in this disease. Years ago we utilized adriamycin, largely because there were no other agents! We should have learned from studies, albeit ear...

Comments

Medical Oncologist at Regional Cancer Care Associates, LLC
Is there any role for VEGF inhibitors along with a...

Medical Oncologist at NYU Winthrop Hospital
Atezolizumab/Bevacizumab

Related Questions